Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral develops devices for unmet medical needs. Sepsis occurs in 1.7M Americans/year causing 250K deaths, often caused by endotoxin. Our devices measure and remove endotoxin from the bloodstream. An FDA confirmatory trial is underway. Dialco, a Spectral sub, offers SAMI, a novel instrument for renal replacement, cleared by FDA. Dialco is seeking FDA approval for DIMI a unique home dialysis enabler. These devices have large commercial potential


TSX:EDT - Post by User

Comment by hmmmmmmmmon Mar 06, 2024 6:38pm
127 Views
Post# 35919288

RE:This is more or less what was said...

RE:This is more or less what was said...Yes, Dr Kellum has been very clear and consistent that they "will not conduct any formal analysis" and that "conducting interim analysis would result in statistical penalties".

He has also been consistant and clear that "crude data" is not statistical analysis- as printed/ stated twice in the AGM. This was the case until we reached 90 and at the behest of Baxter the difference was erased.

It should also be noted that no current results from the Tigris trial are included in the Baysian Statistical Analysis paper. It is historical numbers from Euphrates and hypothetical results.
<< Previous
Bullboard Posts
Next >>